Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Oxaliplatin

Oxaliplatin Reactions 1680, p271 - 2 Dec 2017 Neuropathy: case report A man developed [age at the time of reaction onset not clearly stated] developed neuropathy during therapy with oxaliplatin [route, dosage and duration of treatment to reaction onset not stated]. The man with a history of metastatic colon cancer, presented for further care in May 2016 at the age of 62 years. Eleven years before the presentation, in August 2005, he was diagnosed with stage III colon cancer. On 23 August 2005, he underwent a subtotal colectomy. In 2005, he received treatment with FOLFOX regimen that included fluorouracil [5-fluorouracil], folinic acid [leucovorin] and oxaliplatin. However, he developed grade 1 neuropathy due to oxaliplatin and intermittent haematuria of unknown aetiology. In April 2015, he developed new liver lesions consistent with metastatic colon adenocarcinoma. From April 2015 to December 2015, he was treated with FOLFIRI regimen consisting of fluorouracil [5-fluorouracil], folinic acid [leucovorin] and irinotecan with bevacizumab. However, the FOLFIRI regimen was stopped due to disease progression in the liver. He was then treated with Irinotecan and Cetuximab from December 2015 to April 2016, but therapy was discontinued due to disease progression in the liver and lymph nodes, as well as http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Oxaliplatin

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Download PDF
1 page

Oxaliplatin

Abstract

Reactions 1680, p271 - 2 Dec 2017 Neuropathy: case report A man developed [age at the time of reaction onset not clearly stated] developed neuropathy during therapy with oxaliplatin [route, dosage and duration of treatment to reaction onset not stated]. The man with a history of metastatic colon cancer, presented for further care in May 2016 at the age of 62 years. Eleven years before the presentation, in August 2005, he was diagnosed with stage III colon cancer. On 23 August 2005, he...
Loading next page...
 
/lp/springer_journal/oxaliplatin-RxvRgBcC2G

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-017-39202-7
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p271 - 2 Dec 2017 Neuropathy: case report A man developed [age at the time of reaction onset not clearly stated] developed neuropathy during therapy with oxaliplatin [route, dosage and duration of treatment to reaction onset not stated]. The man with a history of metastatic colon cancer, presented for further care in May 2016 at the age of 62 years. Eleven years before the presentation, in August 2005, he was diagnosed with stage III colon cancer. On 23 August 2005, he underwent a subtotal colectomy. In 2005, he received treatment with FOLFOX regimen that included fluorouracil [5-fluorouracil], folinic acid [leucovorin] and oxaliplatin. However, he developed grade 1 neuropathy due to oxaliplatin and intermittent haematuria of unknown aetiology. In April 2015, he developed new liver lesions consistent with metastatic colon adenocarcinoma. From April 2015 to December 2015, he was treated with FOLFIRI regimen consisting of fluorouracil [5-fluorouracil], folinic acid [leucovorin] and irinotecan with bevacizumab. However, the FOLFIRI regimen was stopped due to disease progression in the liver. He was then treated with Irinotecan and Cetuximab from December 2015 to April 2016, but therapy was discontinued due to disease progression in the liver and lymph nodes, as well as

Journal

Reactions Weekly – Springer Journals

Published: Dec 2, 2017

There are no references for this article.